What We Do | Vektor Medical

Vektor Medical, Inc.

The Next Generation In Non-Invasive Arrhythmia Mapping

Vektor Medical was established to improve cardiac arrhythmia care and increase patient quality of life. We have developed a patented, next-generation technology designed for functionally mapping cardiac arrhythmias. Vektor’s vMap™ technology is rapid, non-invasive, and optimized for the clinical workflow. vMap™ harnesses the power of computational modeling to analyze the information contained in a patient’s standard ECG.

vMap™ has been designed to provide the physician with activation source information, for evaluation, investigation, and potential treatment within a matter of minutes.

Vektor Medical innovates smart, non-invasive cardiac arrhythmia mapping tools that aim to improve first pass ablation success and reduce overall procedure time.

Traditional mapping techniques are labor intensive¹, lengthy², and often provide incomplete information³.

vMap™ harnesses the power of non-invasive data to simplify cardiac mapping. Combining proprietary computational modeling and 12-lead ECG data, vMap enables mapping of stable and unstable rhythms to assist the physician in improving cardiac arrhythmia care.

THE vMAP™ DIFFERENCE

WHOLE HEART NON-INVASIVE MAPPING

Comprehensive multi-chamber mapping that can map arrhythmias in < 3 minutes

SMART ARRHYTHMIA SOURCE MAPPING

Advanced, proprietary algorithm generates beat-by-beat 2D & 3D cardiac maps to precisely locate potential ablation sites.

SIMPLE WORKFLOW

5-step workflow simplifies setup and training while significantly reducing overall fluro exposure

1. Krummen DE, Baykaner T, Schricker AA, Kowalewski CAB, Swarup V, Miller JM, Tomassoni GF, Park S, Viswanathan MN, Wang PJ, Narayan SM. Multicentre safety of adding focal impulse and rotor modulation (firm) to conventional ablation for atrial fibrillation. Europace.
2017;19:769-774.
2. Cano O, Plaza D, Sauri A, Osca J, Alonso P, Andres A, Sancho-Tello MJ, Martinez-Dolz L. Utility of high-density multielectrode mapping during ablation of scar-related ventricular tachycardia. J Cardiovasc Electrophysiol. 2017;28:1306-1315.
3. Anter E. Limitations and pitfalls of substrate mapping for ventricular tachycardia. JACC Clin Electrophysiol. 2021;7:542-560.

vMap™ has been cleared by the U.S FDA and is now commercially available across the United States.